| Subject: | Increased Risk of Lymphoma in Children, Adolescents Treated with TNF Blockers Described in Boxed Warning |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 4 Aug 2009 - 06:00 pm |
| The FDA has notified healthcare professionals that it has completed its analysis of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) and has concluded that there is an increased risk of lymphoma and other cancers associated with the use of these drugs in children and adolescents. This new safety information is now being added to the Boxed Warning for these products. TNF blockers are approved for the treatment of one or more of a number of immune... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
